Share this

HAP / VAP

Reference:

  1. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111.
  2. Foundation for the National Institute of Health.FNIH. Considerations for clinical trial design for the study of hospital-acquired bacterial pneumonia and ntilator-associated bacterial pneumonia. Foundation for the NIH Biomarkers Consortium HABP/VABP Project Team, My 26, 2017. fnih.org/what-we-do/biomarkers-consortium/programs/ventilator-acquired-bacterial -pneumonia. Accessed November 6, 2024
  3. Cilloniz C, Martin-Loeches I, Garcia-Vidal C, San Jose A, Torres A. Microbial etiology of pneumonia: epidemiology, dagnosis and resistance patterns. Int J Mol Sci. 2016;17(12):2120. pii: E2120. doi:10.3390/ijms17122120.

Reference:

  1. Talbot GH, Das A, Cush S, Dane A, Wible M, Echols R, Torres A, Cammarata S, Rex JH, Powers JH, Fleming T, Loutit J, Hoffmann S; Foundation for the National Institutes of Health Biomarkers Consortium HABP/VABP Project Team.Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. J Infect Dis. 2019 Apr 19;219(10):1536-1544. doi: 10.1093/infdis/jiy578. PMID: 30649434; PMCID:PMC6562159.

Reference:

  1. Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage Pseudomonas aeruginosa infections. Drugs Context. 2018 May 29;7:212527. doi: 10.7573/dic.212527. PMID: 29872449; PMCID: PMC5978525.
  2. Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016;56(1):56-66.

References

  1. Jamal J-A, Abdul-Aziz M-H, Lipman J, Roberts JA. Defining antibiotic dosing in lung infections. Clin Pulm Med.2013;20:121-128.
  2. Sattar SBA, Sharma S. Bacterial Pneumonia. [Updated 2019 Feb 11]. In: StatPearls [Internet]. Treasure Island (FL):StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513321. Last access date 11/11/2024

Reference

  1. Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107-1121

References

  1. Jamal J-A, Abdul-Aziz M-H, Lipman J, Roberts JA. Defining antibiotic dosing in lung infections. Clin Pulm Med.2013;20:121-128.
  2. Pajot O, Lakhal K, Lambert J, Gros A, Bruel C, Boulain T, Garot D, Das V, Timsit JF, Cerf C, Souweine B, Chaffaut C, Mentec H, Zahar JR, Mira JP, Jullien V. Empirical Antibiotic Therapy for Gram-Negative Bacilli Ventilator-Associated Pneumonia: Observational Study and Pharmacodynamic Assessment. Antibiotics (Basel). 2022 Nov 19;11(11):1664.doi: 10.3390/antibiotics11111664. PMID: 36421308; PMCID: PMC9686941.

References

  1. Välitalo PA, Griffioen K, Rizk ML, Visser SA, Danhof M, Rao G, van der Graaf PH, van Hasselt JG. Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid. Pharm Res. 2016 Apr;33(4):856-67. doi: 10.1007/s11095-015-1832-x. Epub 2015 Dec 1. PMID: 26626793
  2. Jamal J-A, Abdul-Aziz M-H, Lipman J, Roberts JA. Defining antibiotic dosing in lung infections. Clin Pulm Med. 2013;20:121-128.
  3. Pajot O, Lakhal K, Lambert J, Gros A, Bruel C, Boulain T, Garot D, Das V, Timsit JF, Cerf C, Souweine B, Chaffaut C, Mentec H, Zahar JR, Mira JP, Jullien V. Empirical Antibiotic Therapy for Gram-Negative Bacilli Ventilator-Associated Pneumonia: Observational Study and Pharmacodynamic Assessment. Antibiotics (Basel). 2022 Nov 19;11(11):1664. doi: 10.3390/antibiotics11111664. PMID: 36421308; PMCID: PMC9686941.

Reference

  1. Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107-1121

AE-NON-00509 | Exp 30 Sept 2026